GSK plc Reports Share Transaction Activity
Ticker: GLAXF · Form: 6-K · Filed: Jul 29, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, disclosure, 6-K
TL;DR
GSK bought/sold its own shares in July 2025. Details in 6-K.
AI Summary
GSK plc announced a transaction in its own shares on July 29, 2025. The filing, a Form 6-K, details the company's activities regarding its share repurchases or other transactions involving its own stock. This report is filed monthly for the period ending July 2025.
Why It Matters
This filing provides insight into GSK's capital allocation strategy and its ongoing management of its share structure.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not indicate any immediate financial distress or significant new risks.
Key Players & Entities
- GSK plc (company) — Registrant
- July 2025 (date) — Reporting period
- 20250729 (date) — Filing date
- 001-15170 (other) — SEC file number
FAQ
What type of transaction in its own shares did GSK plc report for July 2025?
The filing is a Form 6-K reporting a 'Transaction in own shares' for the month of July 2025, but the specific details of the transaction (e.g., buyback, sale) are not elaborated in the provided header information.
What is the filing date for this report?
The filing date for this report is 20250729.
What is the SEC file number for GSK plc?
The SEC file number for GSK plc is 001-15170.
What is the principal executive office address for GSK plc?
The principal executive office address for GSK plc is 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 29, 2025 regarding GSK plc (GLAXF).